Ticagrelor vs. Clopidogrel for Coronary Artery Disease
Trial Summary
Will I have to stop taking my current medications?
The trial requires participants to be on low-dose aspirin and clopidogrel for at least 24 hours after the procedure. If you are currently taking prasugrel, ticagrelor, or certain other medications, you may need to stop those before joining the trial.
What data supports the effectiveness of the drug Ticagrelor for coronary artery disease?
Research shows that Ticagrelor is more effective than Clopidogrel in reducing heart attacks, strokes, or cardiovascular deaths in patients with acute coronary syndromes. It also has a faster onset of action and provides greater inhibition of platelet aggregation, which helps prevent blood clots.12345
Is Ticagrelor safe for humans?
Ticagrelor is generally well tolerated but can cause some side effects like shortness of breath and heart rhythm issues. It has a warning for bleeding risks, which is common for drugs that prevent blood clots. Most people handle it well, but it's important to discuss any concerns with a doctor.12456
What makes the drug Ticagrelor unique for treating coronary artery disease?
What is the purpose of this trial?
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10). We hypothesize that ticagrelor is associated with better pharmacodynamic effects (i.e., lower platelet reactivity and high platelet reactivity rates) compared with clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention with a high ABCD-GENE score.
Research Team
Francesco Franchi, MD
Principal Investigator
Univesrsity of Florida
Eligibility Criteria
This trial is for stable coronary artery disease patients undergoing elective heart procedure (PCI), aged 18 or older, with no recent heart attack and on low-dose aspirin plus clopidogrel. They must have a high genetic risk score (ABCD-GENE ≥10) and normal or slightly elevated troponin levels. Excluded are those with allergies to the drugs being tested, certain other medications, severe liver disease, low blood counts, potential bradycardia without a pacemaker, active bleeding issues, or women not using contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either low-dose ticagrelor or clopidogrel to assess antiplatelet effects
Follow-up
Participants are monitored for safety and effectiveness after treatment, including platelet reactivity measurements
Treatment Details
Interventions
- Clopidogrel
- Ticagrelor
Ticagrelor is already approved in United States, European Union for the following indications:
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
Scott R. MacKenzie Foundation
Collaborator